➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Baxter
Johnson and Johnson
Harvard Business School
AstraZeneca
Mallinckrodt
McKinsey

Last Updated: October 28, 2020

DrugPatentWatch Database Preview

Claims for Patent: 4,000,256

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 4,000,256
Title: Varicella vaccine and process for its preparation
Abstract:Preparation of safe, live, attenuated varicella virus vaccine by serial propagation of varicella virus in tissue cell culture systems.
Inventor(s): Hilleman; Maurice R. (Lafayette Hill, PA), Buynak; Eugene B. (North Wales, PA), Neff; Beverly J. (Harleysville, PA)
Assignee: Merck & Co., Inc. (Rahway, NJ)
Application Number:05/592,562
Patent Claims:1. A process for the preparation of a live attenuated, cell-free varicella virus useful as an antigen in a vaccine, which will evoke in man an antibody response against a virulent varicella virus without causing the severe clinical manifestations of the disease which comprises serially passaging the virulent virus from about 10 to about 80 times at 30.degree.-38.degree. C. in a tissue culture preparation selected from the group consisting of human and animal diploid cell strains and primary cells of simian origin to attenuate the virus followed by release of the attenuated virus from the infected cell by sonication in the presence of a stabilizer comprising sucrose, albumin, glutamine and phosphate.

2. The process of claim 1 wherein the serial passaging is at 32.degree. C.

3. The process of claim 1 wherein the serial passaging is at 32.degree. C. and 36.degree. C.

4. The process of claim 1 wherein the tissue culture preparation is of human diploid cell strains.

5. The process of claim 4 wherein the human diploid cell strain is human fetal lung tissue.

6. The process of claim 5 wherein the human fetal lung tissue is WI-38.

7. The process of claim 1 wherein the tissue culture preparation is of primary cells of simian origin.

8. The process of claim 7 wherein the primary cells of simian origin are of monkey testicular tissue.

9. The process of claim 1 wherein the tissue culture preparation is of animal diploid cell strain.

10. The process of claim 9 wherein the animal diploid cell strain is of fetal rhesus tissue.

11. The process of claim 6 wherein the stabilizer is SPGA.

12. A live, attenuated cell-free varicella vaccine comprising an immunologically effective amount of a live attenuated cell-free varicella virus prepared by the process of serially passaging the virulent virus from about 10 to about 80 times at 30.degree.-38.degree. C. in a tissue culture preparation selected from the group consisting of human and animal diploid cell strains and primary cells of simian origin to attenuate the virus followed by release of the attenuated virus from the infected cell by sonication in the presence of a stabilizer comprising sucrose, albumin, glutamine and phosphate in combination with a carrier comprising sterile water.

13. The vaccine of claim 10 wherein the serial passaging is at 32.degree. C. and 36.degree. C.

14. The vaccine of claim 12 wherein the tissue culture preparation is of human diploid cell strains.

15. The vaccine of claim 14 wherein the human diploid cell strain is human fetal lung tissue.

16. The vaccine of claim 15 wherein the human fetal lung tissue is WI-38.

17. The vaccine of claim 16 wherein the stabilizer is SPGA.

18. The varicella vaccine of claim 12 is wet-frozen form.

19. The varicella vaccine of claim 12 in lyophilized form.

20. A method of providing immunity against varicella which comprises the administration of the varicella vaccine of claim 12.

Details for Patent 4,000,256

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Merck Sharp & Dohme Corp. ZOSTAVAX zoster vaccine live INJECTION, POWDER, LYOPHILIZED, FOR SUSPENSION 125123 001 2006-05-25   Start Trial Merck & Co., Inc. (Rahway, NJ) 1993-12-28 search
Merck Sharp & Dohme Corp. ZOSTAVAX zoster vaccine live INJECTION, POWDER, LYOPHILIZED, FOR SUSPENSION 125123 1 2006-05-25   Start Trial Merck & Co., Inc. (Rahway, NJ) 1993-12-28 search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Mallinckrodt
Baxter
Moodys
Merck
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.